Ipsen's Rare Liver Disease Treatment Gets FDA OK
By Ben Glickman
Ipsen's treatment for the rare liver disease primary biliary cholangitis on Monday received approval from U.S. regulators.
The French pharmaceutical company said Iqirvo, which goes by the generic name elafibranor, had received accelerated approval from the U.S. Food and Drug Administration for the treatment of PBC, in combination with ursodeoxycholic acid.
The company said Iqirvo could be prescribed immediately in the U.S. for patients who have an inadequate response to ursodeoxycholic acid or as a monotherapy in patients who cannot tolerate ursodeoxycholic acid.
Ipsen has submitted Iqirvo for approval by European and U.K. regulators, with decisions expected in the second half of the year.
PBC is a rare autoimmune disease that involves a build-up of bile and toxins and chronic inflammation. It affects about 100,000 people in the U.S., Ipsen said.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
June 10, 2024 17:24 ET (21:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying